The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
As the company prepares to host its first investor day in over a decade the focus falls on underappreciated in-house assets.
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
Following its voclosporin's phase III lupus hit Aurinia intends to launch in the US on its own, but seeks partners for other areas.
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.
With data showing superiority over glucocorticoids, Chemocentryx could have a new standard of care for vasculitis in avacopan.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Astrazeneca’s goal of bringing the second new lupus drug in over half a century to the market is a step closer, but all hangs on the FDA accepting mixed clinical data.